Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Partial-Breast Radiation Therapy in Treating Women With Early-Stage Breast Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2011 by National Cancer Institute (NCI).
Recruitment status was  Not yet recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: November 4, 2009
Last updated: May 25, 2011
Last verified: February 2011

RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. It may also cause less damage to normal tissue.

PURPOSE: This phase II trial is studying how well partial-breast radiation therapy works in treating women with early-stage breast cancer.

Condition Intervention Phase
Breast Cancer
Procedure: adjuvant therapy
Radiation: accelerated partial breast irradiation
Radiation: intracavitary balloon brachytherapy
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Primary Purpose: Treatment
Official Title: A Single Institution, Prospective, Non-randomized Study of Partial Breast Irradiation Using the MammoSite Radiation Therapy System (Breast Brachytherapy Applicator)

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Proportion of local recurrence at 5 years [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety and toxicity [ Designated as safety issue: Yes ]
  • Cosmetic results as assessed at baseline, 6 months, and 30 months [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: August 2009
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Detailed Description:



  • To examine the efficacy of MammoSite® Radiation Therapy System (RTS) in delivering partial-breast irradiation to women with early-stage breast cancer.


  • To assess the toxicities associated with MammoSite® RTS in these patients.
  • To evaluate the cosmetic results in the breast after brachytherapy with the MammoSite® RTS.
  • To correlate the cosmetic results with the use of chemotherapy, volume of the implant, and distance from the implant to the skin.
  • To correlate the local recurrence rate with time between surgery and implant.

OUTLINE: Patients undergo placement of the MammoSite® Radiation Therapy System (RTS) device into the cavity where the tumor was removed either at the time of surgery or percutaneously under ultrasound guidance after surgery. Within 2-5 days after the device implant, patients undergo partial-breast irradiation delivered by MammoSite® RTS twice daily for 5 days.

After completion of study therapy, patients are followed up periodically for 5 years.


Ages Eligible for Study:   45 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Histologically confirmed ductal carcinoma in situ (DCIS) of the breast or invasive breast adenocarcinoma

    • Stage 0, I, or II (T2, N0; tumor size ≤ 3 cm) disease
    • Pathologic staging of the axilla preferred

      • Clinical staging of the axilla allowed for patients ≥ 70 years of age with hormone receptor-positive tumors
  • Unicentric tumor

    • Microscopic multifocality allowed as long as the total tumor size is ≤ 3 cm
  • Must have undergone lumpectomy as definitive surgery

    • Negative surgical margins, defined as no tumor at the inked margin of resection after final surgery

      • Re-excision to obtain negative margins allowed
  • Must have adequate skin spacing between balloon surface and surface of the skin and lung (≥ 7 mm)
  • No multicentric carcinoma (invasive or DCIS) in more than one quadrant
  • No clinically or pathologically positive regional lymph nodes
  • No extensive intraductal component, defined as DCIS extending beyond the primary invasive component into normal breast parenchyma and composing > 25% of the primary tumor
  • Hormone receptor status not specified


  • Menopausal status not specified
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No collagen-vascular disease, including any of the following:

    • Dermatomyositis
    • Systemic lupus erythematosus
    • Scleroderma-mixed connective tissue disease


  • See Disease Characteristics
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01008514

Sponsors and Collaborators
Ohio State University Comprehensive Cancer Center
Principal Investigator: Edward Kim, MD Ohio State University Comprehensive Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: Edward Kim, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center Identifier: NCT01008514     History of Changes
Other Study ID Numbers: CDR0000651359, OSU-08177, 2009C0041
Study First Received: November 4, 2009
Last Updated: May 25, 2011
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
ductal breast carcinoma in situ
stage IA breast cancer
stage IB breast cancer
stage II breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms by Site
Skin Diseases processed this record on November 23, 2014